Skinvisible, Inc. (SKVI) income statement
SKVIOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 0/30
$0.16+0.00 (+0.06%)
Close on Oct 19, 2026Market cap $843.54KP/E –Yield –
Skinvisible, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 100.0%
- Operating margin
- -2294.9%
- Net margin
- -5156.6%
- Return on equity, FY2025
- 10.9%
Financial strength
- Current ratio
- 0.01
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 0.1%
Valuation
- P/E ratio
- –
- Price to sales
- 42.18
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?